ClinicalTrials.gg

Program

pegcetacoplan

Also written as “Pegcetacoplan”, “APL-2” and “PEGCETACOPLAN (APL-2)”.

Its studies are mostly in Geographic Atrophy · Hemoglobinuria, Paroxysmal · Glomerulonephritis, Membranoproliferative · Anemia, Hemolytic, Autoimmune · Macular Degeneration, led by 4 companies.

Furthest: phase 4, since Apr 10, 201830 company-led studies, 7 open or runningNext primary completion: Jun 25, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Biogen244 open or runningphase 3since Apr 10, 2018Oct 8, 2014Jun 25, 2027phase 2 · NCT07215390
Swedish Orphan Biovitrum42 open or runningphase 4since Mar 26, 2026Oct 15, 2021Jan 17, 2031phase 3 · NCT07898774
AbbVie11 open or runningphase 2since Aug 12, 2025Aug 12, 2025Oct 2029phase 2 · NCT07160179
Hoffmann-La Roche10 open or runningphase 1since Apr 29, 2025Apr 29, 2025none ahead

Also a collaborator on its studies: iqvia-pty-ltd.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 16 studies since Oct 8, 2014.

  1. Feb 23, 2021Phase 3 study in Geographic Atrophy Secondary to Age-related Macular DegenerationBiogen · NCT04770545 · 792 enrolled · United States, Argentina, Australia and more
  2. Mar 8, 2021Phase 2 study in Hemoglobinuria, ParoxysmalBiogen · NCT04901936 · 12 planned · United States, Czechia, France and more
  3. Sep 23, 2021Phase 3 study in Glomerulonephritis, MembranoproliferativeBiogen · NCT05067127 · 124 enrolled · United States, Argentina, Australia and more
  4. Oct 15, 2021Swedish Orphan Biovitrum's first study: phase 3 study in Anemia, Hemolytic, AutoimmuneNew to Swedish Orphan BiovitrumSwedish Orphan Biovitrum · NCT05096403 · 24 enrolled · United States, Austria, Belgium and more
  5. Oct 21, 2021Phase 2 study in Transplant-Associated Thrombotic MicroangiopathySwedish Orphan Biovitrum · NCT05148299 · 12 enrolled · United States, France, Greece and more
  6. Mar 30, 2023Phase 3 study in Glomerulonephritis, MembranoproliferativeBiogen · NCT05809531 · 100 enrolled · United States, Argentina, Australia and more
  7. Apr 29, 2025Hoffmann-La Roche's first study: phase 1 study in Geographic AtrophyNew to Hoffmann-La RocheHoffmann-La Roche · NCT06961370 · 27 enrolled · United States
  8. Jun 6, 2025Phase 3 study in Delayed Graft FunctionBiogen · NCT07020832 · Brazil
  9. Jun 30, 2025Phase 2 study in Geographic Atrophy Secondary to Age-related Macular DegenerationBiogen · NCT07215390 · 240 planned · United States
  10. Aug 12, 2025AbbVie's first study: phase 2 study in Geographic AtrophyNew to AbbVieAbbVie · NCT07160179 · 66 planned · United States
  11. Sep 15, 2025Phase 3 study in FSGSBiogen · NCT07213960 · 270 planned · United States
  12. Oct 6, 2025Phase 3 study in Geographic AtrophyBiogen · NCT07214740 · 44 enrolled · United States
  13. Mar 26, 2026Phase 4 study in GlomerulonephritisSwedish Orphan Biovitrum · NCT07746895 · 150 planned · Australia, Austria, Belgium and more
  14. Oct 21, 2026Phase 3 study in C3 Glomerulopathy (C3G), Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)Swedish Orphan Biovitrum · NCT07898774 · 30 planned · Brazil, Canada, Finland and more

Ahead

  1. Jun 25, 2027Primary completion: phase 2 study in Geographic Atrophy Secondary to Age-related Macular DegenerationBiogen · NCT07215390
  2. Jul 2027Primary completion: phase 3 study in Glomerulonephritis, MembranoproliferativeBiogen · NCT05809531
  3. Dec 2028Primary completion: phase 2 study in Hemoglobinuria, ParoxysmalBiogen · NCT04901936
  4. Oct 2029Primary completion: phase 3 study in FSGSBiogen · NCT07213960

TargetBeta

C3 →read by rule
“A pegylated peptide inhibitor of human complement components C3 and C3b, ”NCIt, by rule
“Complement C3 inhibitor”ChEMBL 37, by rule

Other programs on C3

ProgramCompanyFurthest phaseStudies
SSS55rule3SBiophase 11

Studies

All 30 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07898774C3 Glomerulopathy (C3G), Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) · Brazil, Canada, Finland and more3RecruitingSwedish Orphan BiovitrumJan 17, 203130
NCT07746895Glomerulonephritis · Australia, Austria, Belgium and more4RecruitingSwedish Orphan BiovitrumDec 31, 2031150
NCT07214740Geographic Atrophy · United States3CompletedBiogenDec 12, 202544
NCT07213960FSGS · United States3RecruitingBiogenOct 2029270
NCT07160179Geographic Atrophy · United States2RecruitingAbbVieOct 202966
NCT07215390Geographic Atrophy Secondary to Age-related Macular Degeneration · United States2RecruitingBiogenJun 25, 2027240
NCT07020832Delayed Graft Function · Brazil3WithdrawnBiogenJun 20290
NCT06961370Geographic Atrophy · United States1TerminatedHoffmann-La RocheFeb 3, 202627
NCT05809531Glomerulonephritis, Membranoproliferative · United States, Argentina, Australia and more3Active, not recruitingBiogenJul 2027100
NCT05148299Transplant-Associated Thrombotic Microangiopathy · United States, France, Greece and more2CompletedSwedish Orphan BiovitrumDec 8, 202412
NCT05096403Anemia, Hemolytic, Autoimmune · United States, Austria, Belgium and more3CompletedSwedish Orphan BiovitrumMay 27, 202424
NCT05067127Glomerulonephritis, Membranoproliferative · United States, Argentina, Australia and more3CompletedBiogenJun 26, 2024124
NCT04901936Hemoglobinuria, Paroxysmal · United States, Czechia, France and more2RecruitingBiogenDec 202812
NCT04770545Geographic Atrophy Secondary to Age-related Macular Degeneration · United States, Argentina, Australia and more3CompletedBiogenSep 5, 2025792
NCT04572854Glomerulonephritis, Membranoproliferative · United States, Argentina, Australia and more2CompletedBiogenFeb 27, 202313
NCT04579666Amyotrophic Lateral Sclerosis · United States, Australia, Belgium and more2TerminatedBiogenMar 31, 2023249
NCT04085601Hemoglobinuria, Paroxysmal · Colombia, Hong Kong, Malaysia and more3CompletedBiogenJun 23, 202153
NCT03777332Geographic Atrophy · United States1CompletedBiogenApr 1, 202119
NCT03593200Hemoglobinuria, Paroxysmal · Bulgaria, Serbia2CompletedBiogenOct 22, 20194
NCT03531255PNH · United States, Australia, Belgium and more3CompletedBiogenSep 4, 2025137
NCT03525613Geographic Atrophy · United States, Australia, Brazil and more3CompletedBiogenJun 28, 2021637
NCT03525600Geographic Atrophy · United States, Argentina, Australia and more3CompletedBiogenJun 21, 2021621
NCT03500549Hemoglobinuria, Paroxysmal · United States, Australia, Belgium and more3CompletedBiogenNov 14, 201980
NCT03465709Neovascular Age-related Macular Degeneration · United States2TerminatedBiogenApr 5, 201917
NCT03453619Glomerulonephritis, IGA · United States2CompletedBiogenApr 16, 202021
NCT03226678Anemia, Hemolytic, Autoimmune · United States2CompletedBiogenSep 12, 202224
NCT02588833Hemoglobinuria, Paroxysmal · Hong Kong, Malaysia, New Zealand and more1CompletedBiogenAug 26, 201923
NCT02503332Geographic Atrophy · United States, Australia, New Zealand2CompletedBiogenJul 14, 2017246
NCT02461771Neovascular Age-Related Macular Degeneration · United States, Australia1CompletedBiogenMar 8, 201613
NCT02264639Hemoglobinuria, Paroxysmal · United States1CompletedBiogenOct 22, 20189

How it is read

Names in the registry

  • “Pegcetacoplan”, 17 entries
  • “APL-2”, 7 entries
  • “PEGCETACOPLAN (APL-2)”, 2 entries
  • “APL-3007, pegcetacoplan (APL-2)”, 2 entries
  • “Syfovre™”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.